三阴性乳腺癌诊治若干进展  

Certain progress in diagnosis and treatment of triple negative breast cancer

作　　者：贾实[1] 马瑶 赵毅[1] JIA Shi;MA Yao;ZHAO Yi(Department of Oncology,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院肿瘤外科,辽宁沈阳110014

出　　处：《中国实用外科杂志》2021年第11期1243-1248,共6页Chinese Journal of Practical Surgery

基　　金：2019年辽宁省自然科学基金指导计划项目(No.2019-ZD-0780)。

摘　　要：三阴性乳腺癌具有侵袭性强,预后差的特点,并具有很强的异质性。因此,明确三阴性乳腺癌的各类亚型对其诊断与治疗非常重要,根据其亚型所呈现的不同生物学及临床特征采取不同的治疗方案才有可能得到良好的治疗效果。虽然化疗仍是目前三阴性乳腺癌的治疗核心,但近年来大量研究开始聚焦于三阴性乳腺癌的亚分型,并依据亚分型的不同开发了多种新的治疗手段,如针对胚系BRCA突变的多聚腺苷二磷酸-核糖聚合酶(PARP)抑制剂,以及针对免疫检查点[程序性死亡分子及配体(PD-1/PD-L1)]的免疫检查点抑制剂与白蛋白紫杉醇联合治疗等,对于三阴性乳腺癌而言,个体化、精准化的诊治是未来发展的趋势。Triple negative breast cancer is characterized by strong invasiveness,poor prognosis and strong heterogeneity.Therefore,it is very important to identify the various subtypes of triple negative breast cancer for its diagnosis and treatment.It is possible to obtain good therapeutic effects by adopting different treatment schemes according to the different biological and clinical characteristics of its subtypes.Although chemotherapy is still the main treatment for triple negative breast cancer,a large number of studies have begun to focus on the subtypes of triple negative breast cancer and a variety of new treatment methods have been developed according to the different subtypes in recent years.For example,the poly adenosine diphosphate ribose polymerase(PARP)inhibitors for germline BRCA mutations,and the albumin paclitaxel combined with immunological checkpoint inhibitors for immunological checkpoints(PD-L1+).Personalized and precise diagnosis and treatment is the trend of future development for the triple negative breast cancer,

关 键 词：三阴性乳腺癌 亚分型 

分 类 号：R737.9[医药卫生—肿瘤]